

Long noncoding RNA AFAP1-AS1 promoted osteosarcoma proliferation and invasion via upregulating BDNF

B.-M. ZHAO^{1,2}, F.-H. CHENG³, L. CAI²

¹Department of Orthopaedic Surgery, The No. 1 People's Hospital of Jinzhou, Jinzhou, China

²Department of Orthopaedic Surgery, Zhongnan Hospital Affiliated to Medical College of Wuhan University, Wuhan, China

³Department of Orthopedics, Weinan Central Hospital, Weinan, China

Abstract. – OBJECTIVE: Recently, long non-coding RNAs (lncRNAs) have got much attention for their role in tumor progression. LncRNA AFAP1-AS1 was studied in this research to identify how it affects the development and proliferation of osteosarcoma.

PATIENTS AND METHODS: The mRNA expression of AFAP1-AS1 in osteosarcoma cells and tissue samples was detected by quantitative real-time polymerase chain reaction (qPCR). Moreover, cell proliferation assay and migration assay were performed. Furthermore, the underlying mechanism was explored by using Western blot and Western blot assay.

RESULTS: The expression level of AFAP1-AS1 was higher in osteosarcoma tissues than that in adjacent tissues. In addition, the proliferation and invasion were inhibited after AFAP1-AS1 was downregulated in vitro. Besides, BDNF mRNA and protein expression level of osteosarcoma neurotrophic factor (BDNF) was reduced after downregulation of AFAP1-AS1. Moreover, the expression level of BDNF was positively related to the expression of AFAP1-AS1 in osteosarcoma tissues.

CONCLUSIONS: AFAP1-AS1 could enhance the proliferation and invasion of osteosarcoma cells by upregulating BDNF, which might be a potential therapeutic target in osteosarcoma.

Key words: Long noncoding RNA AFAP1-AS1, Osteosarcoma, BDNF.

Introduction

Osteosarcoma is the most common primary malignant bone tumor with a peak incidence in children and adolescents, which presents with a highly malignant tendency to damage the sur-

rounding tissues¹. Approximately 4 million cases of newly diagnosed osteosarcoma per year around the world with a poor prognosis and a high rate of disability in youth, which brings a heavy burden to patients and society^{2,3}. The main treatments include surgery, chemotherapy and radiotherapy. Despite of the developing therapeutic strategies, almost 80% of patients who underwent surgical treatment finally developed current metastasis and their 5-year survival rate remains 50–60%^{4,5}. Therefore, it is urgent to realize the underlying molecular mechanism of osteosarcoma tumorigenesis and find out new therapeutic targets. Long noncoding RNAs (lncRNAs) are defined as ncRNAs which are more than 200 nucleotides in length. Recently, lncRNAs have got much attention for their functions in cellular processes, including the cell proliferation, cell invasion and chromatin remodeling. For example, through targeting MUC2 and up-regulating miR-34c, lncRNA AF147447 represses gastric cancer proliferation and invasion⁶. LncRNA NR_036575.1 acts as an oncogene in papillary thyroid cancer by enhancing the proliferation and migration⁷. In addition, lncRNA linc00261 functions as a tumor suppressor in gastric cancer through depressing the stability of Slug proteins and inhibiting epithelial-mesenchymal transition⁸. However, the clinical role and biological mechanism of lncRNA AFAP1-AS1 in the development of osteosarcoma remain unexplored. In this study, we found out that the expression of AFAP1-AS1 was remarkably higher in osteosarcoma tissues. In addition, AFAP1-AS1 promoted the proliferation and invasion of osteosarcoma *in vitro*. Moreover, our further investigation explored the underlying

mechanism how AFAP1-AS1 functioned in the development and proliferation of osteosarcoma.

Patients and Methods

Patients

A total of 40 paired osteosarcoma and adjacent non-tumor tissues were sequentially gathered from patients who received surgery at Zhongnan Hospital Affiliated to Medical College of Wuhan University. Before operation, written informed consent was achieved. No radiotherapy or chemotherapy for any patients before the operation. All tissues were analyzed by an experienced pathologist. The Ethics Committee of Zhongnan Hospital Affiliated to Medical College of Wuhan University approved this study protocol.

Cell Culture

Human osteosarcoma cell lines MG-63, U2OS, Saos-2 and SOSP-9607 and osteoblastic cell line hFOB 1.19 were purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Science (Shanghai, China). Culture medium consisted of 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), penicillin as well as Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Rockville, MD, USA). Culture atmosphere was an incubator containing 5% CO₂ and set at 37°C.

Cell Transfection

After synthesized, AFAP1-AS1 shRNA, short-hairpin RNA (shRNA) was cloned into pcDNA3.1 (GenePharma, Shanghai, China). 293T cells were used for packaging AFAP1-AS1 shRNA (shRNA) and empty vector (EV). Then shRNA (shRNA) and empty vector (EV) were used for osteosarcoma cell transfection. Then detection of AFAP1-AS1 expression level in these cells was conducted using quantitative real-time polymerase chain reaction (qRT-PCR).

RNA Extraction and qRT-PCR

The total RNA was separated by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). And then the total RNA was reverse-transcribed to complementary deoxyribose nucleic acids (cDNA) using reverse Transcription Kit (TaKaRa Biotechnology Co., Ltd., Dalian, China). Following are the primers using for qRT-PCR: AFAP1-AS1 primers forward 5'-AGCCTGTTGAATCAGCCAAC-3', reverse 5'-GGTTCAT-

ACCAGCCCTGTCC-3'; β -actin primers forward 5'-CCAACCGCGAGAAGATGA-3' and reverse 5'-CCAGAGGCGTACAGGGATAG-3'. The PCR cycle was as follows: 30 s at 95°C for 40 cycles at 95°C, 35 s at 60°C. 2^{- $\Delta\Delta$ Ct} method was utilized for calculating relative expression.

Western Blot Analysis

Reagent radioimmuno precipitation (RIPA) was utilized for extracting protein from cells. Bicinchoninic acid (BCA) protein assay kit (TaKaRa Biotechnology Co., Ltd., Dalian, China) was chosen for quantifying protein concentrations. The target proteins were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Then they were incubated with antibodies after replaced to the polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Antibodies included rabbit anti- β -actin, rabbit anti-BDNF (brain derived neurotrophic factor) and goat anti-rabbit secondary antibody (Cell Signaling Technology, Danvers, MA, USA). Image J software (National Institutes of Health, Bethesda, MD, USA) was performed to assess the protein expression.

Tube Formation Assay

5×10⁴ cells in 200 μ L serum-free DMEM were transformed to top chamber of an 8 μ m pore size insert (Corning, Corning, NY, USA) coated with 50 μ g Matrigel (BD, Bedford, MA, USA). And the lower chamber was added DMEM and FBS. After wiped by cotton swab, the top surface of chambers was immersed for 10 min with precooling methanol. Following were stain in crystal violet for 30 min. Three fields were used to count the data.

Statistical Analysis

Statistical Product and Service Solutions (SPSS) 18.0 (SPSS Inc., Chicago, IL, USA) was adopted to conduct the statistical analysis. Student *t*-text was performed to the data. Data were presented as mean \pm SD (standard deviation). It was considered of statistically significance, when $p < 0.05$.

Results

AFAP1-AS1 Expression Level in Osteosarcoma Tissues and Cells

First, qRT-PCR was conducted for detecting the mRNA expression of AFAP1-AS1 in 40 patients' tissues and 4 osteosarcoma cell lines. The




Figure 1. Expression levels of AFAP1-AS1 were increased in osteosarcoma tissues and cell lines. **A**, AFAP1-AS1 expression was significantly increased in the osteosarcoma tissues compared with adjacent tissues. **B**, Expression levels of AFAP1-AS1 relative to β -actin were determined in the human osteosarcoma cell lines and hFOB 1.19 (osteoblastic cell line) by qRT-PCR. Data are presented as the mean \pm standard error of the mean. * $p < 0.05$.

results of qRT-PCR showed that AFAP1-AS1 was significantly upregulated in tumor tissue samples compared with adjacent normal tissues (Figure 1A). Meanwhile, the mRNA expression of AFAP1-AS1 in osteosarcoma cells was higher than that in hFOB 1.19 (osteoblastic cell line) (Figure 1B).

Downregulation of AFAP1-AS1 Repressed Cell Proliferation in Osteosarcoma Cells

In our study, we chose U2OS and Saos-2 osteosarcoma cell lines for the downregulation of AFAP1-AS1. Then qRT-PCR was used for detecting the mRNA expression of AFAP1-AS1 (Figure 2A). Moreover, the results of cell proliferation assay revealed that after AFAP1-AS1 was downregulated, the cell growth ability was sig-

nificantly inhibited in U2OS osteosarcoma cells (Figure 2B). Meanwhile, results of cell proliferation assay also revealed that after AFAP1-AS1 was downregulated, the cell growth ability was significantly inhibited in Saos-2 osteosarcoma cells (Figure 2C).

Downregulation of AFAP1-AS1 Repressed Cell Invasion in Osteosarcoma Cells

The results of Matrigel assay also revealed that after AFAP1-AS1 was downregulated in U2OS osteosarcoma cells, the number of invaded cells was remarkably decreased (Figure 3A). Meanwhile, the results of matrigel assay also showed that after AFAP1-AS1 was downregulated in Saos-2 osteosarcoma cells, the number of invaded cells was remarkably reduced (Figure 3B).




Figure 2. Downregulation of AFAP1-AS1 repressed osteosarcoma cell proliferation. **A**, AFAP1-AS1 expression in osteosarcoma cells transfected with AFAP1-AS1 shRNA (shRNA) and the empty vector (EV) was detected by qRT-PCR. β -actin was used as an internal control. **B**, Cell proliferation assay showed that downregulation of AFAP1-AS1 significantly repressed cell viability in U2OS osteosarcoma cells. **C**, Cell proliferation assay showed that downregulation of AFAP1-AS1 significantly repressed cell viability in Saos-2 osteosarcoma cells. The results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$.




Figure 3. Downregulation of AFAP1-AS1 suppressed osteosarcoma cell invasion. **A**, Matrigel assay showed that the number of invaded cells was significantly decreased *via* downregulation of AFAP1-AS1 in U2OS osteosarcoma cells. **B**, Matrigel assay showed that the number of invaded cells was significantly decreased *via* downregulation of AFAP1-AS1 in Saos-2 osteosarcoma cells. The results represent the average of three independent experiments (mean \pm standard error of the mean). * $p < 0.05$.

The Interaction Between BDNF and AFAP1-AS1 in Osteosarcoma

qRT-PCR results showed that compared with empty vector (EV) group, expression level of BDNF in osteosarcoma cells was lower in AFAP1-AS1 shRNA (shRNA) group (Figure 4A). Western blot assay found out that after AF-

AP1-AS1 was downregulated, the protein expression level of BDNF could be downregulated (Figure 4B). In addition, we further found that the BDNF expression in osteosarcoma tissues was obviously higher than that in adjacent tissues (Figure 4C). Furthermore, correlation analysis demonstrated that the BDNF expression level was




Figure 4. Interaction between AFAP1-AS1 and BDNF. **A**, qRT-PCR results showed that BDNF expression was lower in AFAP1-AS1 shRNA (shRNA) compared with the empty vector (EV). **B**, Western blot assay revealed that BDNF protein expression was reduced in AFAP1-AS1 shRNA (shRNA) compared with the empty vector (EV). **C**, BDNF was significantly up-regulated in osteosarcoma tissues compared with adjacent tissues. **D**, The expression level of BDNF was positively associated with AFAP1-AS1 in osteosarcoma tissues. The results represent the average of three independent experiments. Data are presented as the mean \pm standard error of the mean. * $p < 0.05$.

positively correlated with the expression level of AFAP1-AS1 in osteosarcoma tissues (Figure 4D).

Discussion

A plenty of lncRNAs have been revealed to play an important role in the oncogenesis and progression of osteosarcoma. For example, lncRNA TUG1 functions as a ceRNA of miR-335-5p and facilitates the migration and invasion of osteosarcoma⁹. By sponging miR-326, lncRNA SNHG1 facilitates tumorigenesis in osteosarcoma through regulation of NOB1 expression¹⁰. lncRNA MEG3 inhibits the proliferation and metastasis of osteosarcoma through depressing Notch and TGF- β signaling pathway¹¹. Knockdown of lncRNA NEAT1 reduces the proliferation and invasion of osteosarcoma *via* inhibiting miR-194 expression¹². lncRNA PVT1 promotes glucose metabolism, cell motility, cell proliferation and tumor progression in osteosarcoma by regulating miR-497/HK2 axis¹³. The proliferation and migration of ovarian cancer are inhibited after knockdown of lncRNA MNX1-AS1, which may offer a potential target for ovarian cancer¹⁴. In addition, by interacting with miR-21-5p, lncRNA H19 represses the proliferation and metastasis of osteosarcoma through regulating the expression of PDCD4¹⁵. lncRNA AFAP1-AS1 is transcribed from the antisense strand of the AFAP1 coding gene locus. Recently, several reports have revealed that AFAP1-AS1 is closely related with various cancers. For instance, knockdown of AFAP1-AS1 depresses the proliferation and induces the cell apoptosis in lung adenocarcinoma, which could offer a new therapeutic strategy for the treatment of lung adenocarcinoma. Overexpression of AFAP1-AS1 induced cell apoptosis and regulated the cell proliferation in gastric cancer through PTEN/p-AKT pathway¹⁷. Co-expression of AFAP1-AS1 and PD-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma, and those patients may be ideal candidates for anti-PD-1 immune therapy¹⁸. Moreover, AFAP1-AS1 promoted tumorigenesis in esophageal squamous cell carcinoma by inhibiting cell apoptosis and promoting cell proliferation¹⁹. Our study demonstrated that AFAP1-AS1 was upregulated in osteosarcoma tissues and cells. Furthermore, after AFAP1-AS1 was downregulated, the proliferation and invasion of osteosarcoma cells were inhibited. Above results indicated that AFAP1-AS1 could promote tumorigenesis of osteo-

sarcoma and might act as an oncogene. Brain-derived neurotrophic factor (BDNF), as a member of the neurotrophin superfamily, has been demonstrated to participate in the pathophysiology of nervous system. Recent reports have indicated that BDNF plays an important role in the growth and invasion of various cancers. For instance, BDNF signaling pathway plays an important role in the early recurrence of triple-negative breast cancer and affects its prognosis²⁰. MicroRNA-155-5p functioned as a tumor suppressor in human hepatocellular carcinoma through targeting BDNF²¹. BDNF was upregulated in human thyroid cancer tissues which could reverse the growth suppressive function of miR-497²². Moreover, activated by STAT3, BDNF promoted the proliferation of human non-small-cell lung cancer *via* regulating TrkB signaling pathway. In the present study, BDNF expression could be inhibited after downregulation of AFAP1-AS1. Moreover, BDNF expression in osteosarcoma tissues was positively correlated with AFAP1-AS1 expression. All those results above suggested that AFAP1-AS1 might promote tumorigenesis of osteosarcoma *via* targeting BDNF.

Conclusions

We demonstrated that the expression of AFAP1-AS1 was remarkably upregulated in osteosarcoma tissues. In addition, AFAP1-AS1 enhanced the proliferation and invasion of osteosarcoma cells through targeting BDNF. Our findings suggested that AFAP1-AS1 could be a candidate target in the treatment of osteosarcoma.

Conflict of Interest

The Authors declare that they have no conflict of interest.

References

- 1) LINK MP, GOORIN AM, MISER AW, GREEN AA, PRATT CB, BELASCO JB, PRITCHARD J, MALPAS JS, BAKER AR, KIRKPATRICK JA. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 1986; 314: 1600-1606.
- 2) KJETIL B, TOM B RGE J, AASMUND B, HANS KRISTIAN H, BODIL B, B HLER PJ, YVIND SB. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. *Acta Oncol* 2015; 54: 25-33.

- 3) LEE L, FEI L, POPE J, WAGNER LM. Early lymphocyte recovery and outcome in osteosarcoma. *J Pediatr Hematol Oncol* 2017; 39: 179-183.
- 4) REHEI AL, ZHANG L, FU YX, MU WB, YANG DS, LIU Y, ZHOU SJ, YOUNUSI A. MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. *Eur Rev Med Pharmacol Sci* 2018; 22: 5156-5164.
- 5) SONG QC, SHI ZB, ZHANG YT, JI L, WANG KZ, DUAN DP, DANG XO. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients. *Oncol Rep* 2014; 31: 1263-1270.
- 6) ZHOU X, CHEN H, ZHU L, HAO B, ZHANG W, HUA J, GU H, JIN W, ZHANG G. Helicobacter pylori infection related long noncoding RNA (lncRNA) AF147447 inhibits gastric cancer proliferation and invasion by targeting MUC2 and up-regulating miR-34c. *Oncotarget* 2016; 7: 82770-82782.
- 7) SUN W, LAN X, WANG Z, DONG W, HE L, ZHANG T, ZHANG H. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer. *Med Oncol* 2016; 33: 102.
- 8) YU Y, LI L, ZHENG Z, CHEN S, CHEN E, HU Y. Long non-coding RNA linc00261 suppresses gastric cancer progression via promoting Slug degradation. *J Cell Mol Med* 2017; 21: 955-967.
- 9) WANG Y, YANG T, ZHANG Z, LU M, ZHAO W, ZHANG W. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells. *Cancer Sci* 2017; 108: 859-867.
- 10) WANG J, CAO L, WU J, WANG Q. Long non-coding RNA SNHG1 regulates MDR1 expression by sponging miR-326 and promotes chemoresistance in osteosarcoma. *Int J Oncol* 2018; 53: 77-88.
- 11) ZHANG SZ, CAI L, LI B. MicroRNA-101-3p long non-coding RNA prevents cell growth and metastasis in osteosarcoma. *Bratislavskí lekarský časopis* 2017; 118: 632-636.
- 12) WANG H, YU Y, CHEN S, LUO L. Knockdown of long non-coding RNA AFAP1 inhibits proliferation and invasion and induces apoptosis of osteosarcoma by inhibiting miR-194-3p expression. *Yonsei Med J* 2017; 112: 1092-1100.
- 13) SONG Y, WU X, LIU F, LI M, SHI Y, WANG Y, WANG C, CHU K, JIA X, WANG B. Long non-coding RNA AFAP1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. *Biochem Biophys Res Comm* 2017; 490: 217-224.
- 14) LV Y, LI H, LI F, LIU P, ZHAO X. Long Non-coding RNA MNX1-AS1 knockdown inhibits cell proliferation and migration in ovarian cancer. *Cancer Biother Radiopharm* 2017; 32: 91.
- 15) ZHANG R, XIA T. Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis. *Int J Oncol* 2017; 51: 1460-1468.
- 16) ZHUANG Y, JIANG H, CHEN H, DAI J, LIU Y, LI Y, LIU L, CAI H, XIAO Y, ZHANG H. Downregulation of long non-coding RNA AFAP1-AS1 inhibits tumor cell growth and invasion in nasopharyngeal carcinoma. *Am J Transl Res* 2017; 9: 2931-2945.
- 17) GUO JQ, LIU J, GUO GX. Long non-coding RNA AFAP1-AS1 promotes cell proliferation and apoptosis of gastric cancer cells via PTEN/p-AKT pathway. *Dis Dis Sci* 2016; 62: 2004-2010.
- 18) TANG Y, HE Y, SHI L, WANG J, LIAN Y, FAN C, GUO P, GUO C, ZHANG H. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. *Oncotarget* 2017; 8: 39001-39011.
- 19) LUO HL, HUANG D, GUO JN, FAN RH, XIA XT, HE JD, CHEN XF. AFAP1-AS1 is upregulated and promotes proliferation of squamous cell carcinoma cell proliferation and inhibits cell apoptosis. *Cancer Med* 2016; 5: 2879-2885.
- 20) YE, TSENG LM, HSU CY, YANG MH, CHIU JH, SHYR Y. Brain-derived neurotrophic factor (BDNF)-TrkB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer. *PLoS One* 2017; 12: e0178173.
- 21) LONG J, JIANG C, LIU B, SHI F, MING K. MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. *Tumor Biol* 2016; 37: 5821-5828.
- 22) WANG P, MENG X, HUANG Y, LV Z, LIU J, WANG G, MENG W, XUE S, ZHANG Q, ZHANG P. MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF. *Oncotarget* 2017; 8: 2825-2834.
- 23) OKAMURA K, HARADA T, WANG S, IJICHI K, FURUYAMA K, KOGA T, OKAMOTO T, TAKAYAMA K, YANO T, NAKANISHI Y. Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. *Lung Cancer* 2012; 78: 100-106.